Various clinical studies have found lower sFRP5 serum levels in obese, T2D, and CHD patients—all high-risk groups for VC—suggesting a critical function for sFRP5 in the healthy vasculature [66,98,99]. Here, SFRP5 is linked to type 2 diabetes mellitus.